Tess A. O’Meara

765 total citations
25 papers, 403 citations indexed

About

Tess A. O’Meara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Tess A. O’Meara has authored 25 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Tess A. O’Meara's work include Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (6 papers) and Advanced Breast Cancer Therapies (4 papers). Tess A. O’Meara is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (6 papers) and Advanced Breast Cancer Therapies (4 papers). Tess A. O’Meara collaborates with scholars based in United States, Poland and Italy. Tess A. O’Meara's co-authors include Sara M. Tolaney, Lajos Pusztai, Tao Qing, Michał Marczyk, Christos Hatzis, Andrea Silber, Jasmine Wong, Michael J. Campbell, Rita A. Mukhtar and Zelos Zhu and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Tess A. O’Meara

24 papers receiving 400 citations

Peers

Countries citing papers authored by Tess A. O’Meara

Since Specialization

Citations

This map shows the geographic impact of Tess A. O’Meara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tess A. O’Meara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tess A. O’Meara more than expected).

Fields of papers citing papers by Tess A. O’Meara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tess A. O’Meara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tess A. O’Meara. The network helps show where Tess A. O’Meara may publish in the future.

Co-authorship network of co-authors of Tess A. O’Meara

This figure shows the co-authorship network connecting the top 25 collaborators of Tess A. O’Meara. A scholar is included among the top collaborators of Tess A. O’Meara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tess A. O’Meara. Tess A. O’Meara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Different Diseases, Different Escapes: Trastuzumab Deruxtecan Resistance in HER2-Amplified versus HER2-Low Breast Cancer 2026 ·Cancer Discovery ·Tess A. O’Meara, Paolo Tarantino	0
2	Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer 2025 ·JNCI Journal of the National Cancer Institute ·Paolo Tarantino, (unknown), Julia Foldi, Pamela R. Soulos, Cary P. Gross, Tess A. O’Meara, Thomas Grinda, Stefania Morganti, Adrienne G. Waks, Eric P. Winer, Nancy U. Lin, Ian E. Krop, (unknown), Sarah Sammons, Maryam B. Lustberg	4
3	Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing 2025 ·Current Oncology Reports ·Tess A. O’Meara, Paolo Tarantino, Stefania Morganti, Ilana Schlam, Ana C. Garrido-Castro, Sara M. Tolaney	3
4	SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. 2024 ·Journal of Clinical Oncology ·Ana C. Garrido-Castro, Se Eun Kim, (unknown), Rita Nanda, Lisa A. Carey, Amy S. Clark, (unknown), (unknown), Natalie Sinclair, K. M. Steve Lo, Amy Thomas, Eileen Wrabel, Tess A. O’Meara, Nancy U. Lin, Harold J. Burstein, (unknown), David L. Rimm, Elizabeth A. Mittendorf, Nabihah Tayob, Sara M. Tolaney	20
5	Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ , and healthy women 2024 ·mSystems ·(unknown), Anukriti Sharma, (unknown), Tess A. O’Meara, (unknown), Maribel Campos, Diane Heditsian, Susie Brain, Jack A. Gilbert, Laura Esserman, Michael J. Campbell	5
6	Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes 2022 ·Clinical Epigenetics ·(unknown), Erin Hofstatter, Zuyun Liu, Tess A. O’Meara, Anna Maria Storniolo, D. Dalela, Vineet K. Singh, Lajos Pusztai, Morgan E. Levine	10
7	Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer 2022 ·npj Breast Cancer ·Michał Marczyk, Tao Qing, Tess A. O’Meara, (unknown), Vasiliki Pelekanou, Yalai Bai, Emily Reisenbichler, Kimberly Cole, Xiaotong Li, Vignesh Gunasekharan, Eiman Ibrahim, (unknown), Wei Wei, David L. Rimm, Lajos Pusztai, Kim Blenman	9
8	Abstract P1-04-05: Multiplexed immunofluorescence staining of intra-tumoral immune cell populations and associations with immunohistochemical, clinical, and pathologic variables in breast cancer 2022 ·Cancer Research ·Tess A. O’Meara, Tanya E. Keenan, Adrienne G. Waks, Kristen D. Felt, Bijaya Sharma, Scott J. Rodig, Melissa E. Hughes, Nancy U. Lin, Judith Agudo, Jennifer L. Guerriero, Sandra S. McAllister, Elizabeth A. Mittendorf, Sara M. Tolaney	2
9	Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control study 2021 ·Breast Cancer Research ·Vesal Yaghoobi, Myrto Moutafi, Thazin Nwe Aung, Vasiliki Pelekanou, (unknown), Kim Blenman, Eiman Ibrahim, (unknown), Saba Shafi, Anup Sharma, Tess A. O’Meara, Aileen I. Fernandez, Lajos Pusztai, David L. Rimm	6
10	Tumor mutational burden as a predictor of immunotherapy response in breast cancer 2021 ·Oncotarget ·Tess A. O’Meara, Sara M. Tolaney	73
11	Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden 2020 ·Nature Communications ·Tao Qing, Hussein Mohsen, Michał Marczyk, Yixuan Ye, Tess A. O’Meara, Hongyu Zhao, Jeffrey P. Townsend, Mark Gerstein, Christos Hatzis, Yuval Kluger, Lajos Pusztai	49
12	Abstract P3-09-05: Predictive markers of response to durvalumab concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) neoadjuvant therapy for triple negative breast cancer (TNBC) 2020 ·Cancer Research ·Kim Blenman, Xiaotong Li, Michał Marczyk, Tess A. O’Meara, Vesal Yaghoobi, Vignesh Gunasekharan, (unknown), David L. Rimm, Lajos Pusztai	2
13	Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers 2020 ·JCO Precision Oncology ·Tess A. O’Meara, Michał Marczyk, Tao Qing, Vesal Yaghoobi, Kim Blenman, Kimberly Cole, Vasiliki Pelekanou, David L. Rimm, Lajos Pusztai	32
14	Neuraxial Anesthesia for Hybrid Lower Extremity Revascularization Is Associated With Reduced Perioperative Morbidity 2019 ·Journal of Vascular Surgery ·Arash Fereydooni, Tess A. O’Meara, Wanda M. Popescu, Alan Dardik, Cassius Iyad Ochoa Chaar	1
15	Use of neuraxial anesthesia for hybrid lower extremity revascularization is associated with reduced perioperative morbidity 2019 ·Journal of Vascular Surgery ·Arash Fereydooni, Tess A. O’Meara, Wanda M. Popescu, Alan Dardik, Cassius Iyad Ochoa Chaar	8
16	Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women 2019 ·Breast Cancer Research and Treatment ·Tess A. O’Meara, Anton Safonov, David Casadevall, Tao Qing, Andrea Silber, Brigid K. Killelea, Christos Hatzis, Lajos Pusztai	42
17	Exosomal MicroRNAs Associate With Neuropsychological Performance in Individuals With HIV Infection on Antiretroviral Therapy 2019 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Tess A. O’Meara, Yong Kong, Jennifer Chiarella, Richard W. Price, (unknown), Xinran Liu, Serena Spudich, Kevin Robertson, Brinda Emu, Lingeng Lu	14
18	Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor–Positive Breast Cancer: Clinical Versus Molecular Tools 2019 ·Journal of Clinical Oncology ·Julia Foldi, Tess A. O’Meara, Michał Marczyk, Tara Sanft, Andrea Silber, Lajos Pusztai	20
19	Abstract 2830: Breast cancer and the human oral and gut microbiomes 2019 ·Cancer Research ·Michael J. Campbell, (unknown), (unknown), Tess A. O’Meara, Diane Heditsian, Susie Brain, Laura Esserman	1
20	Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast 2016 ·Breast Cancer Research and Treatment ·Michael J. Campbell, Frederick L. Baehner, Tess A. O’Meara, (unknown), Booyeon J. Han, Rita A. Mukhtar, Vickram J. Tandon, (unknown), Zelos Zhu, Jasmine Wong, Gregor Krings, Alfred Au, Joe W. Gray, Laura J. Esserman	84

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact